Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.
Navaira Shoaib, MBBS
Advertisement
Articles by Navaira Shoaib, MBBS
Advertisement
Latest Updated Articles
GLP-1 Receptor Agonists: Trend, Necessity, or Blessing?December 8th 2025
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
4
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
5